Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00423930 · OUTCOME

Overall Survival Rate: Percentage of Participants Who Survived

Cisplatin, Bevacizumab, and Intensity-Modulated Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer · Source last updated 2017-08-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
95% Confidence Interval
Time frame
2 years

Groups in this outcome

IMRT + Cisplatin + Bevacizumab

This is a single-institution phase II study. The primary endpoint is to determine 2-year progression-free survival for patients with locally or regionally advanced HNSCC treated with concurrent intensity modulated radiation therapy (IMRT) + cisplatin + bevacizumab. bevacizumab cisplatin conventional surgery intensity-modulated radiation therapy

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
IMRT + Cisplatin + Bevacizumab42

Reported measurements

Source class 1
Values in percentage of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
IMRT + Cisplatin + Bevacizumab88Not reported78.698.4Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        78.6
        upper Limit
        98.4
        value
        88
denoms
  1. counts
    1. group Id
      OG000
      value
      42
    units
    Participants
dispersion Type
95% Confidence Interval
groups
  1. description
    This is a single-institution phase II study. The primary endpoint is to determine 2-year progression-free survival for patients with locally or regionally advanced HNSCC treated with concurrent intensity modulated radiation therapy (IMRT) + cisplatin + bevacizumab. bevacizumab cisplatin conventional surgery intensity-modulated radiation therapy
    id
    OG000
    title
    IMRT + Cisplatin + Bevacizumab
param Type
NUMBER
reporting Status
POSTED
time Frame
2 years
title
Overall Survival Rate: Percentage of Participants Who Survived
type
SECONDARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice